| Literature DB >> 24524036 |
Farzaneh Mirzaie1, Gilda Eslami2, Mohammad Hossein Yosefi3, Nader Pestehchian3.
Abstract
BACKGROUND: Cutaneous leishmaniasis (CL) continues to be an increasing public health problem in Iran. The dominant etiologic agents of CL in the Old World are Leishmania major and Leishmania tropica. One of the important endemic foci of CL in Iran is Yazd. Recently, previous studies showed the equal prevalence of L. major and L. tropica as the agents of cutaneous leishmaniasis in this area. This prompted us to identify the genotype of L. major isolates obtained from patients with cutaneous leishmaniasis.Entities:
Keywords: Cutaneous leishmaniasis; identification; internal transcribed spacers1; leishmania major
Year: 2013 PMID: 24524036 PMCID: PMC3908692 DOI: 10.4103/2277-9175.122525
Source DB: PubMed Journal: Adv Biomed Res ISSN: 2277-9175
Figure 1Electrophoresis results of ITS1-PCR from smears. M: Molecular marker (50 bp); Lane 1: Standard Leishmania major (MRHO/IR/75/ER); Lane 2: Standard Leishmania tropica (MHOM/IR/99/YAZ1); Lane 3: Leishmania infantum (MCAN/IR/97/LON49); Lane 4, 5: PCR products sample; Lane 6: PCR product s sample; Lane 7: Negative control
Figure 2Restriction enzyme digestion profile of amplified ITS1 region with the restriction enzyme of HaeIII. M: Molecular marker (50 bp); Lane 1: Standard Leishmania major; Lane 2: Standard Leishmania tropica; Lane 3: Standard Leishmania infantum; Lane 4: Leishmania major; Lane 5: Leishmania tropica; Lane 6: The one sample different from the normal samples and standard patterns; Lane 7: Negative control
The clinical shapes of different forms of ZCL present in Yazd
Figure 3Restriction enzyme digestion profile of amplified ITS1 region from Leishmania major. Giemsa-stained smears with the enzyme TaqI. M: Molecular marker (50 bp); Lane 1: Standard Leishmania major with TaqI; Lane 2: LmA1 (130 and 200 bp) Leishmania major; Lane 3: LmA2 (210 bp and 150 bp); Lane 4: LmA3 (210 bp and 120 bp); Lane 5: LmA4 (200 bp and 145 bp); Lane 6: Negative control
Figure 4Restriction enzyme digestion profile of amplified ITS1